Actively Recruiting

Age: 18Years +
All Genders
NCT06180434

Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas

Led by Erasmus Medical Center · Updated on 2024-10-15

320

Participants Needed

1

Research Sites

78 weeks

Total Duration

On this page

Sponsors

E

Erasmus Medical Center

Lead Sponsor

M

Medical Center Haaglanden

Collaborating Sponsor

AI-Summary

What this Trial Is About

Rationale: Proton beam therapy has recently become available for the treatment of patients with WHO grade 2 and 3 IDH mutated (IDHmt) glioma in the Netherlands. The dose distributions associated with proton therapy have substantially reduced the volume of the normal brain irradiated with low and intermediate radiotherapy doses. Whether this impacts rates of progressive disease or safety issues and how this compares with a similar population treated with photon therapy is currently unknown. Objective: To investigate short term outcomes after proton and photon radiotherapy for grade 2 and 3 IDHmt glioma.

CONDITIONS

Official Title

Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histopathologically confirmed WHO grade 2 or grade 3 IDH mutated glioma
  • Radiotherapy treatment delivered between January 1, 2018, and completed on or before June 30, 2022
  • Chemotherapy given after radiotherapy with PCV or Temozolomide
  • Age 18 years or older
Not Eligible

You will not qualify if you...

  • Prior cranial radiotherapy
  • Contraindication for MRI imaging
  • Chemotherapy given before radiotherapy
  • Radiotherapy dose and fractionation different from standard (50.4 Gy in 28 fractions for grade 2; 59.5 Gy in 33 fractions for grade 3)
  • Combination of photon and proton therapy
  • Patient previously opted out of use of their data for research

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Erasmus MC

Rotterdam, Netherlands

Actively Recruiting

Loading map...

Research Team

S

Steven HJ Nagtegaal, MD PhD

CONTACT

A

Alejandra Mendez Romero, MD PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas | DecenTrialz